COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)-Reference-Cited by-同舟云学术

COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)

Published:2023-09-06 Issue: Volume: Page:1-12
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Kandarakis Stylianos¹^ORCID,Papadopoulos Alexandros P.²,Roussopoulos Georgios²,Georgopoulos Eustathios²,Chung Youngsik³,Doumazos Leonidas¹,Baek Areum³,Paizi Nefeli Ioanna²^ORCID,Shin Hyunik³,Papadopoulos Pantelis A.⁴

Affiliation:

1. First Department of Ophthalmology, G. Gennimatas Hospital, National and Kapodistrian University of Athens, Athens, Greece

2. Ophthalmo Check Eye Center, Athens, Greece

3. R&D center, Yonsung Fine Chemicals Co., Ltd. / YS Life Science Co., Ltd, Suwon-si, South Korea

4. Metropolitan Hospital, Athens, Greece

Funder

Yonsung GmbH

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2252341

Reference39 articles.

1. Primary open-angle glaucoma

2. Latanoprost in the treatment of glaucoma

3. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients

4. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension

5. A review of the use of latanoprost for glaucoma since its launch